NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News

$16.30

+0.50 (+3.16 %)

(As of 06/3/2020 11:43 AM ET)

Add

Compare

Today's Range

$15.75

Now: $16.30▼

$16.60

50-Day Range

$13.80

MA: $17.33▼

$19.70

52-Week Range

$10.63

Now: $16.30▼

$28.81

Volume67,861 shs

Average Volume130,666 shs

Market Capitalization$535.46 million

P/E RatioN/A

Dividend YieldN/A

Beta1.27

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.00, Crinetics Pharmaceuticals has a potential upside of 117.5% from its current price of $16.09.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Crinetics Pharmaceuticals has received 84 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Crinetics Pharmaceuticals has received 97 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Crinetics Pharmaceuticals has received 53.59% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,884,993.00 in company stock.
Percentage Held by Insiders
Only 7.10% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
62.97% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($2.47) to ($2.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.36 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CRNX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.crinetics.com

Phone858-450-6464

Debt

Debt-to-Equity Ratio0.04

Current Ratio10.89

Quick Ratio10.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.19 million

Price / Sales449.96

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.84 per share

Price / Book3.37

Profitability

EPS (Most Recent Fiscal Year)($2.09)

Net Income$-50,420,000.00

Net MarginsN/A

Return on Equity-47.28%

Return on Assets-42.59%

Miscellaneous

Employees47

Outstanding Shares32,850,000

Market Cap$535.46 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

How has Crinetics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has increased by 3.8% and is now trading at $16.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crinetics Pharmaceuticals.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Crinetics Pharmaceuticals.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced its quarterly earnings results on Friday, May, 8th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.08. The company had revenue of $0.07 million for the quarter. View Crinetics Pharmaceuticals' earnings history.

What price target have analysts set for CRNX?

3 brokerages have issued 1-year target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $38.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $35.00 in the next year. This suggests a possible upside of 117.5% from the stock's current price. View analysts' price targets for Crinetics Pharmaceuticals.

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

News coverage about CRNX stock has been trending neutral on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutCrinetics Pharmaceuticals.

Who are some of Crinetics Pharmaceuticals' key competitors?

Some companies that are related to Crinetics Pharmaceuticals include Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX), Principia Biopharma (PRNB), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Ligand Pharmaceuticals (LGND), Passage Bio (ZNTL), Epizyme (EPZM), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH) and Zymeworks (ZYME). View all competitors.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Immunomedics (IMMU), SCYNEXIS (SCYX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Apellis Pharmaceuticals (APLS).

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:

Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (10.11%), RA Capital Management L.P. (5.97%), 5AM Venture Management LLC (7.58%), BlackRock Inc. (2.94%), Janus Henderson Group PLC (1.50%) and Burrage Capital Management LLC (0.86%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View institutional ownership trends for Crinetics Pharmaceuticals.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., UBS Group AG, Alps Advisors Inc., and Hershey Trust Co.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Ventures Iv LP 5Am, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Burrage Capital Management LLC, Geode Capital Management LLC, Alliancebernstein L.P., Janus Henderson Group PLC, BNP Paribas Arbitrage SA, and Citigroup Inc.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $16.09.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $528.56 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff